A COMPREHENSIVE ANALYSIS OF CANNABIS’S THERAPEUTIC POTENTIAL IN RELATION TO THE HUMAN BODY
DOI:
https://doi.org/10.22159/ajpcr.2025v18i9.54183Keywords:
Cannabidiol, Cannabis, Endocannabinoid system, Marijuana, TetrahydrocannabinolAbstract
Cannabis has emerged as a subject of intense scientific interest due to its multifaceted therapeutic potential across a broad spectrum of human physiological and pathological conditions. This comprehensive analysis explores the pharmacological properties, therapeutic applications, and mechanistic insights of cannabis and its bioactive constituents, primarily cannabinoids such as delta-9-tetrahydrocannabinol and cannabidiol, to the human endocannabinoid system. The manuscript delves into the roles of cannabis in pain modulation, neuroprotection, inflammation, psychiatric disorders, oncology, and gastrointestinal and metabolic disorders, supported by both pre-clinical and clinical findings. Emphasis is placed on the interaction between cannabinoids and cannabinoid receptors (CB1 and CB2), as well as non-cannabinoid targets, illustrating the systemic effects of cannabis on homeostasis and disease modulation. While the therapeutic promise of cannabis is compelling, the analysis also highlights the challenges posed by dosage standardization, psychoactive side effects, legal restrictions, and limited long-term safety data. This review underscores the necessity for rigorous, evidence-based research and regulatory frameworks to unlock the full medicinal potential of cannabis while ensuring patient safety and therapeutic efficacy.
Downloads
References
1. Abel EL. Marijuana: The First Twelve Thousand Years. New York: Plenum Press; 1980.
2. Aldrich MR. Tantric cannabis use in India. J Psychedel Drugs. 1977;9(3):227-33. doi: 10.1080/02791072.1977.10472053
3. Bloomquist ER. Marijuana: The Second Trip. Revision edition. Beverly Hills, CA: Glencoe Press; 1971.
4. Consumer Reporter. Licit and Illicit Drugs. Boston: Little, Brown & Company; 1972.
5. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73. doi: 10.1001/jama.2015.6358, PMID 26103030
6. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: National Academies Press; 2017.
7. Brick JM. Pamphlet Series – Alcohol Studies Archives [Internet]. Available from: https://sites.rutgers.edu/alcoholstudies-archives/ pamphlet-series
8. Carter WE. Cannabis in Costa Rica. Philadelphia, PA: Institute for the Study of Human Issues; 1980.
9. Carter WE, Doughty PL. Social and cultural aspects of cannabis use in Costa Rica. Ann N Y Acad Sci. 1976;282:2-16. doi: 10.1111/j.1749- 6632.1976.tb49879.x, PMID 1071380
10. Cherek DR, Roache JD, Egil M, Dailis C, Spiga R, Cowail K. Acute effects of marijuana smoking on aggressive, escape, and point-maintained responding of male drug users. Psychopharmacol (Berl). 1973;111:163-8.
11. Cohen S, Andrysiak T. The therapeutic potential of marijuana’s components. Rockville, MD: American Council on Marijuana and other Psychoactive Drugs; 1982.
12. Häuser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - a systematic review. Eur J Pain. 2018;22(3):455-70. doi: 10.1002/ejp.1118, PMID 29034533
13. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. doi: 10.1002/14651858.CD012182. pub2, PMID 29513392
14. Comitas L. Cannabis and work in Jamaica: A refutation of the motivational syndrome. Ann N Y Acad Sci. 1976;282:24-32. doi: 10.1111/j.1749-6632.1976.tb49881.x, PMID 1071382
15. Häuser W, Petzke F, Radbruch L, Fitzcharles MA. Cannabinoids in pain management and palliative medicine. Am J Hosp Palliat Care. 2011;28(1):19-22.
16. Foltin RW, Fischman MW, Brady JV, Bernstein DJ, Capriotti RM, Nellis MJ, et al. Motivation effects of smoked marijuana: Behavioral contingencies and high probability recreational activities. Pharmacol Biochem Behav. 1989;34:871-7.
17. Foltin RW, Fischman MW, Brady JV, Bernstein DJ, Capriotti RM, Nellis MJ, et al. Motivational effects of smoked marijuana: Behavioral contingencies and low probability activities. J Exp Anal Behav. 1990;53(1):5-19. doi: 10.1901/jeab.1990.53-5, PMID 2299291
18. Hepler RS, Petrus RJ. Experience with administration of marijuana to glaucoma patients. In: Cohen S, Stillman RC, editors. The Therapeutic Aspects of Marijuana. New York: Plenum Press; 1976. p. 63-75.
19. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol vs. ondansetron for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2007;15(5):531-7.
20. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy-induced nausea and vomiting: Quantitative systematic review. BMJ. 2001;323(7303):16-21. doi: 10.1136/bmj.323.7303.16, PMID 11440936
21. Cannabis sativa. Available from: https://en.wikipedia.org/wiki/ cannabis_sativa [Last accessed on 2025 Apr 30].
22. Maiston SA, Galizio MG, Connors GJ. Drug use and Abuse. 3rd ed. New York: Harcourt Brace College Publishers; 1999.
23. Martin BR, Cabral G, Childers SR, Deadwyler S, Mechoulam R, Reggio P. Keystone, CO, June 19-20, 1992. Drug Alcohol Depend. 1993;31(3):219-27. doi: 10.1016/0376-8716(93)90004-a, PMID 8462412
24. McGlothlin WH, West LJ. The marijuana problem: An overview. Am J Psychiatry. 1968;125:126-34.
25. Sumitha SK, Pattammady VS, Sambathkumar R. Pharmacology of noval cannabinoids. Int J Pharm Pharm Sci. 2020 Jan 1;12(1):1-5.
26. Todaro C, Schifano F, Prisco V, Nappi G. Use of nabilone in chemotherapy-induced nausea and vomiting. Support Care Cancer. 2012;20(2):439-45.
27. Grotenhermen F, Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Ärztebl Int. 2012;109(29-30):495-501. doi: 10.3238/arztebl.2012.0495, PMID 23008748
28. Goyal H, Rahman MR, Perisetti A, Tharian B, Shiferaw K, Bhattarai M. Cannabis in gastrointestinal disorders: Current status and future directions. World J Gastroenterol. 2017;23(28):5011-20.
29. Cannabis. Available from: https://www.webmd.com/vitamins/ai/ ingredientmono-947/cannabis [Last accessed on 2025 Apr 30].
30. Nahas GG. Marijuana - Deceptive Weed. New York: Raven Press; 1997.
31. National Institute on Drug Abuse (NIDA). Marijuana and Health: Ninth Annual Report to the U.S. Congress from the Secretary of Health and Human Services. Rockville, MD: National Institute on Drug Abuse; 1982.
32. Page JB. The amotivational syndrome hypothesis and the Costa Rica study: Relationship between methods and results. J Psychoactive Drugs. 1983;15(4):261-7. doi: 10.1080/02791072.1983.10471963, PMID 6606701
33. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40(3):695-700. doi: 10.1016/0091-3057(91)90385-f, PMID 1666930
34. Smith DE. Acute and chronic toxicity of marijuana. J Psychoact Drugs. 1968;2(1):37-48. doi: 10.1080/02791072.1968.10524399
35. Sussman S, Stacy AW, Dent CW, Simon TR, Johnson CA. Marijuana use: Current issues and new research directions. J Drug Issues. 1996;26(4):695-733. doi: 10.1177/002204269602600402
36. Ungerleider JT, Andrysiak T. Therapeutic issues of marijuana and THC (tetrahydrocannabinol). Int J Addict. 1985;20(5):691-9. doi: 10.3109/10826088509044289, PMID 2995262
37. Aggarwal SK. Use of cannabinoids in cancer care: Palliative care perspective. J Pain Symptom Manag. 2016;51(2):214-7.
38. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manag. 2010;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008, PMID 19896326
39. Report to the Director, National Institutes of Health, by the ad Hoc Group of Experts Workshop on the Medical Utility of Marijuana. Washington, DC: National Institutes of Health; 1997.
40. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139(4):258-66.
41. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardizedcannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63. doi: 10.1111/j.1365- 2125.2010.03743.x, PMID 21039759
42. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007;68(7):515-21.
43. Suraev AS, Todd L, Bowen MT, Allsop DJ, McGregor IS. Erratum. Med J Aust. 2020;213(6):262. doi: 10.5694/mja2.50725, PMID 32951232
44. Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Curr Oncol. 2016;23(2):S23-32. doi: 10.3747/ co.23.3080, PMID 27022311
45. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
46. Long A, Mioduszewski J, Natale R. A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine. Proc Am Soc Clin Oncol. 1982;1:C-220.
47. Duran M, Pérez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63.
48. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Rodriguez L, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23(3):533-43.
49. Nia AB, Mann C, Khaikin M, Lipp MJ. Medical cannabis use in oncology: A review. JAMA Oncol. 2021;7(8):1200-8.
50. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215.
51. Syroeshkin AV, Galkina DA, Ogotoeva DD, Levitskaya OV, Morozova MA, Pleteneva TV. Comparison of biopharmaceutical parameters of cannabinoids and non-steroidal anti-inflammatory drugs by QSAR method. Int J App Pharm. 2023 Jan 7;15(1):269-73.
52. Lane M, Vogel CL, Ferguson J, Krasnow SH, Saiers JH, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991;6(6):352-9.
53. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Invest New Drugs. 1988;6(3):243-6.
54. Chan HS, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: A double-blind, crossover trial. Pediatrics. 1987;79(6):946-52.
55. Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol. 1986;17(3):285-8.
56. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013;33(2):195-209.
57. Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis Cannabinoid Res. 2017;2(1):139-54.
58. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974-89.
59. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: An alternative antiemetic for cancer chemotherapy. Arch Dis Child. 1986;61(5):502-5.
60. Niederle N, Schütte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. KlinWochenschr. 1986;64(8):362-5.
61. Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs. Sci Rep. 2015;5:8126.
62. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncol. 1985;8(4):336-40.
63. Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 1984;13(2):123-5.
64. George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized comparative trial of a new anti-emetic: Nabilone, in cancer patients treated with cisplatin. Biomed Pharmacother. 1983;37(1):24-7.
65. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA. 2015;313(24):2474-83.
66. Tashkin DP. Effects of marijuana smoking on the lung. Ann Am Thorac Soc. 2013;10(3):239-47.
67. Abrams DI. The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report. Eur J Intern Med. 2018;49:7-11.
68. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treat Rev. 1982;9(Suppl B):25-33.
69. McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? Br J Pharmacol. 2015;172(3):737-53.
70. Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.
71. Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol: Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med. 1980;140(11):1431-3.
72. ElSohly MA, Gul W. Constituents of Cannabis sativa. In: Pertwee RG, editor. Handbook of Cannabis. Oxford: Oxford University Press; 2014. p. 3-22.
73. Walsh Z, Gonzalez R, Crosby K, Serafini K, Pryce J, Thiessen MS, et al. Medical cannabis and mental health: A guided systematic review. Clin Psychol Rev. 2017;51:15-29.
74. Citti C, Braghiroli D, Vandelli MA, Cannazza G. Pharmaceutical and biomedical analysis of cannabinoids: A critical review. J Pharm Biomed Anal. 2018;147:565-79.
75. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin- Santos R, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Curr Pharm Des. 2012;18(32):5131-40.
76. Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol. 1981;21(8-9 Suppl):76S-80.
77. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50(4):636-45.
78. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha-2 adrenoceptor agonist. Br J Pharmacol. 2010;159(1):129-41.
79. Pisanti S, Picardi P, D’Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharmacol Sci. 2013;34(5):273-82.
80. National Institute for Health and Care Excellence (NICE). Excluded studies [Internet]. Evidence Review for Intractable Nausea and Vomiting - NCBI Bookshelf. 2019. Available from: https://www.ncbi. nlm.nih.gov/books/NBK577072/
81. Grunberg SM, Munsell MF, Morrow PK, Giguere JK, Ule UJ, Saccaro SJ, et al. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. J Clin Oncol. 2012;30(15 Suppl):9061.
82. Chan HS, MacLeod SM, Correia JA. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
83. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):239-57.
84. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9- tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
85. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion [Internet]. 2007;23(3):533-43. Available from: https://pubmed.ncbi. nlm.nih.gov/17355735/
86. Ashton CH. Pharmacology and effects of cannabis: A brief review. Br J Psychiatry. 2001;178(2):101-6.
87. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. PubMed [Internet]. 1982. Available from: https:// doi.org/10.1002/1097-0142(19820815)50:4
88. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester JA, Gralla RJ. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979;300(23):1295-7.
89. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992; 16(5):276-82.
90. ElSohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539-48. doi: 10.1016/j.lfs.2005.09.011, PMID 16199061
91. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age. Front Immunol. 2018;9:2009. doi: 10.3389/ fimmu.2018.02009, PMID 30298064
92. Solowij N, Broyd SJ, Greenwood LM, Van Hell HH, Martelozzo D, Rueb K, et al. A randomised controlled trial of vaporised Δ9- tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):17-35. doi: 10.1007/ s00406-019-00978-2, PMID 30661105
93. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by Δ9-THC in normal subjects. Psychopharmacology. 1982;76(3):245-50. doi: 10.1007/BF00432554, PMID 6285406
94. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Annals of Oncology [Internet]. 2010;21(5):1083-8.
95. Mahmud A, Gallant S, Sedki F, Sontineni S, Raj R. The role of medical cannabis in cancer pain management: A review. Cureus. 2021;13(8):e17372.
96. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: From mice to human subjects. PLoS One. 2008;3(2):e1640. doi: 10.1371/journal.pone.0001640, PMID 18286196
99. Train Education. 7 Case Examples of Cannabis Use. aTrain Education. Available from: https://www.atrainceu.com/content/7- case-examples-cannabis-use [Last accessed on 2025 May 12].
100. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of Δ9- tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-74. doi: 10.1038/npp.2009.184, PMID 19924114
101. Verma S, Kumar D, Kumar G, Singh AP. Impending contraceptives that might be A positive methodology towards the male contraception. Int J App Pharm. 2022 Mar 7;14(2):23-34. doi: 10.22159/ ijap.2022v14i2.43941
102. Morales P, Reggio PH, Jagerovic N. An overview on medicinal chemistry of synthetic and natural derivatives of cannabidiol. Front Pharmacol. 2017;8:422. doi: 10.3389/fphar.2017.00422, PMID 28701957
103. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-36. doi: 10.1007/s13311-015- 0387-1, PMID 26341731
104. Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining THC and CBD. Med Hypotheses. 2006;66(2):234-46. doi: 10.1016/j.mehy.2005.08.026, PMID 16209908
105. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-44. doi: 10.1038/nrc3247, PMID 22555283
Published
How to Cite
Issue
Section
Copyright (c) 2025 Jeevanantham I, Jeyaram Bharathi J, Syed Mohamed Omar S, Dhyanesh R, Pavishkumar K
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
